Skip to content

Life Sciences

Every show filed under life sciences, ranked by what listeners actually play.

394
shows
0
subcategories
0
new this week

Most subscribed

audio · in life sciences · refreshed hourly

Newest episodes

audio · last seven days
  • Circulation on the Run

    Circulation September 29, 2026 Issue

    Each week, join Editor-in-Chief Brad Maron, along with cohosts Mercedes Carnethon and Jane Wilcox for the new iteration of Circulation on the Run. This week, Brad and Jane welcome author Alexis F. Guédon to discuss his article "Tocilizumab Is Associated With a Lower Incidence of Major Adverse Cardiovascular Events in Giant Cell Arteritis." Then Deputy Editor Joseph C. Wu joins the podcast to discuss his Research Letter "Modeling Heart Failure With Preserved Ejection Fraction Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes." For the episode transcript, visit: https://www.ahajournals.org/do/10.1161/podcast.20260929.276347

    Yesterday · 43 min
  • Diagnosing Dx

    Will Payer-Dependent Diagnostics Companies Get Left Behind? Marty Keiser, Founder at IVBH / Mammogen

    In this episode of Diagnosing Dx, David Filby is joined by Marty Keiser, Founder and CEO of IVBH. After beginning his career in asset management and capital markets, Marty moved into biotech eight years ago with a focus on blood-based molecular diagnostics and early disease detection. That outside perspective shaped how he built IVBH, borrowing ideas from industries beyond diagnostics to create a different model for developing and scaling diagnostic companies. Marty explains IVBH’s studio model, the science behind its cell-free RNA platform, and how its health franchises are developing tests across breast cancer, lung cancer and metabolic liver disease. We also discuss why traditional diagnostics business models can struggle, the growing opportunity for cash-pay and consumerised testing, and what helped Mammogen secure institutional Series A funding in a difficult market. Key takeaways: 🔹 Why Marty believes the traditional diagnostics business model needs to evolve 🔹 How IVBH uses a central discovery platform to build multiple health franchises 🔹 Why cell-free RNA could offer advantages for earlier disease detection 🔹 How LDTs, cash-pay models and new diagnostic “storefronts” could reshape commercialisation 🔹 What investors looked for when Mammogen raised its Series A Chapters: 01:02 Introduction and Marty Keiser’s background 03:22 Moving from capital markets into diagnostics 08:20 Building the IVBH business model differently 11:27 Surviving the biotech downturn and changing capital markets 16:09 The science behind IVBH’s cell-free RNA platform 20:06 LDTs, cash-pay testing and new commercial models 26:13 What helped Mammogen secure its Series A 30:26 Future milestones and rethinking diagnostics growth Guest: Marty Keiser Founder & CEO, IVBH LinkedIn: https://www.linkedin.com/in/martykeiser Host: David Filby Founder and CEO of Elevra Consulting LinkedIn: https://www.linkedin.com/in/davidfilby/ 🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics and omics.

    Yesterday · 34 min
  • Pharmaceutical Executive

    Pharmaceutical Executive Daily: Fabrice Chouraqui Steps Down as CEO of Pharming

    New U.S. guidance carves out tariff exemptions for specialty pharmaceuticals, Pharming's Fabrice Chouraqui steps down as CEO amid a board rift, and a dealmaking roundup covers Hengrui Pharma's licensing agreement with Novo Nordisk and AstraZeneca's investment in Summit Therapeutics.

    Yesterday · 3 min
  • Razib Khan's Unsupervised Learning

    Kyle Orton: Muslims before Islam

    Today Razib talks to Kyle Orton. Orton is a freelance researcher, writer, and editor specializing in security and foreign policy, with a particular focus on the Middle East, the Syrian war, regional geopolitics, and terrorist movements including the Islamic State (ISIS), Iran's Islamic Revolutionary Guards Corps (IRGC), and the Kurdistan Workers' Party (PKK). His work also ranges widely across history, including early Christianity, Islam and its relationship with the West, intelligence and espionage, the Reformation, the English Civil War, Tsarist Russia and the Soviet Union, the First World War, Communism and the Cold War, and pre-Revolutionary Iran. Orton writes the newsletter It Can Always Get Worse, where he covers contemporary security issues alongside history, religion, intelligence, books, and occasional film reviews. His writing has appeared in publications including The New York Times, The Wall Street Journal, UnHerd, Newsweek, The Independent, The New Arab, and International Business Times. Orton and Razib's conversation begins with his post, The Sojourn of Arculf: An Eyewitness to "Early Islamic" Jerusalem - A Frankish bishop sheds some light on a historical dark age. Their discussion continues with probing the possibility that Islam as we know it truly did not exist any recognizable form before the 690s AD, and that the early "Saracens" as their Christian enemies referred to them were in fact a schismatic group of monotheists whose beliefs were adjacent to that of the Jews. Orton also discusses the role of Muhammad, or rather, the lack of the role of Muhammad, in the early years of the Islamic Caliphate. They also explore the possibility that later commentators largely attributed the negative reputation of Islam's first dynastic Caliphate, the Umayyads, to the reality that they would not recognize them as Muslims. Finally, Orton talks about the reality that some of the layers of text within the Koran seem far older than the time of Muhammad, perhaps by a century or so.

    Yesterday · 51 min

Audio in Life Sciences387